Literature DB >> 22964251

Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.

Xuan Qin1, Danielle M Zerr, Michael A McNutt, Jessica E Berry, Jane L Burns, Raj P Kapur.   

Abstract

Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients undergo remarkable phenotypic divergence over time, including loss of pigmentation, hemolysis, motility, and quorum sensing and emergence of antibiotic hypersusceptibility and/or auxotrophism. With prolonged antibiotic treatment and steady decline in lung function in chronically infected patients, the divergent characteristics associated with CF isolates have traditionally been regarded as "adapted/unusual virulence," despite the degenerative nature of these adaptations. We examined the phenotypic and genotypic diversity in clonally related isogenic strains of P. aeruginosa from individual CF patients. Our observations support a novel model of intra-airway pseudomonal syntrophy and accompanying loss of virulence. A 2007 calendar year collection of CF P. aeruginosa isolates (n = 525) from 103 CF patients yielded in vitro MICs of sulfamethoxazole-trimethoprim (SMX-TMP, which typically has no activity against P. aeruginosa) ranging from 0.02 to >32 μg/ml (median, 1.5). Coisolation of clonally related SMX-TMP-susceptible and -resistant P. aeruginosa strains from the same host was common (57%), as were isogenic coisolates with mutations in efflux gene determinants (mexR, mexAB-oprM, and mexZ) and genes governing DNA mismatch repair (mutL and mutS). In this cohort, complete in vitro growth complementation between auxotrophic and prototrophic P. aeruginosa isogenic strains was evident and concurrent with the coding sequence mosaicism in resistance determinants. These observations suggest that syntrophic clonal strains evolve in situ in an organized colonial structure. We propose that P. aeruginosa adopts a multicellular lifestyle in CF patients due to host selection of an energetically favorable, less-virulent microbe restricted within and symbiotic with the airway over the host's lifetime.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964251      PMCID: PMC3486535          DOI: 10.1128/AAC.01371-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

Review 1.  Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist.

Authors:  J B Lyczak; C L Cannon; G B Pier
Journal:  Microbes Infect       Date:  2000-07       Impact factor: 2.700

2.  Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.

Authors:  Catherine Llanes; Didier Hocquet; Christelle Vogne; Dounia Benali-Baitich; Catherine Neuwirth; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Type VI secretion requires a dynamic contractile phage tail-like structure.

Authors:  M Basler; M Pilhofer; G P Henderson; G J Jensen; J J Mekalanos
Journal:  Nature       Date:  2012-02-26       Impact factor: 49.962

Review 4.  Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance.

Authors:  K Poole; R Srikumar
Journal:  Curr Top Med Chem       Date:  2001-05       Impact factor: 3.295

5.  Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000).

Authors:  Kelley A Gordon; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

Review 6.  Integrons and beta-lactamases--a novel perspective on resistance.

Authors:  Gerhard F Weldhagen
Journal:  Int J Antimicrob Agents       Date:  2004-06       Impact factor: 5.283

Review 7.  Nitric oxide in health and disease of the respiratory system.

Authors:  Fabio L M Ricciardolo; Peter J Sterk; Benjamin Gaston; Gert Folkerts
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

8.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 9.  Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.

Authors:  Margaret Rosenfeld; Bonnie W Ramsey; Ronald L Gibson
Journal:  Curr Opin Pulm Med       Date:  2003-11       Impact factor: 3.155

10.  Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.

Authors:  Xuan Qin; Julia Emerson; Jenny Stapp; Lynn Stapp; Patrick Abe; Jane L Burns
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

View more
  17 in total

Review 1.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

2.  Spatiotemporal Dynamics of Molecular Messaging in Bacterial Co-Cultures Studied by Multimodal Chemical Imaging.

Authors:  Tianyuan Cao; Nydia Morales-Soto; Jin Jia; Nameera F Baig; Sage J B Dunham; Joseph Ellis; Jonathan V Sweedler; Joshua D Shrout; Paul W Bohn
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-03-07

Review 3.  Pseudomonas aeruginosa polymicrobial interactions during lung infection.

Authors:  Karishma Bisht; Jiwasmika Baishya; Catherine A Wakeman
Journal:  Curr Opin Microbiol       Date:  2020-02-12       Impact factor: 7.934

4.  Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Sophie Guénard; Cédric Muller; Laura Monlezun; Philippe Benas; Isabelle Broutin; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

5.  Thrombospondin-1 protects against pathogen-induced lung injury by limiting extracellular matrix proteolysis.

Authors:  Yanyan Qu; Tolani Olonisakin; William Bain; Jill Zupetic; Rebecca Brown; Mei Hulver; Zeyu Xiong; Jesus Tejero; Robert Mq Shanks; Jennifer M Bomberger; Vaughn S Cooper; Michael E Zegans; Hyunryul Ryu; Jongyoon Han; Joseph Pilewski; Anuradha Ray; Zhenyu Cheng; Prabir Ray; Janet S Lee
Journal:  JCI Insight       Date:  2018-02-08

6.  Stability of Cross-Feeding Polymorphisms in Microbial Communities.

Authors:  Ivana Gudelj; Margie Kinnersley; Peter Rashkov; Karen Schmidt; Frank Rosenzweig
Journal:  PLoS Comput Biol       Date:  2016-12-30       Impact factor: 4.475

7.  Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004.

Authors:  Shuai Le; Xuesong He; Yinling Tan; Guangtao Huang; Lin Zhang; Renate Lux; Wenyuan Shi; Fuquan Hu
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

8.  Ex uno plures: clonal reinforcement drives evolution of a simple microbial community.

Authors:  Margie Kinnersley; Jared Wenger; Evgueny Kroll; Julian Adams; Gavin Sherlock; Frank Rosenzweig
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

9.  Environmental heterogeneity drives within-host diversification and evolution of Pseudomonas aeruginosa.

Authors:  Trine Markussen; Rasmus Lykke Marvig; María Gómez-Lozano; Kasper Aanæs; Alexandra E Burleigh; Niels Høiby; Helle Krogh Johansen; Søren Molin; Lars Jelsbak
Journal:  mBio       Date:  2014-09-16       Impact factor: 7.867

10.  Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis.

Authors:  Anna Sze Tai; Scott Cameron Bell; Timothy James Kidd; Ella Trembizki; Cameron Buckley; Kay Annette Ramsay; Michael David; Claire Elizabeth Wainwright; Keith Grimwood; David Mark Whiley
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.